Oncology Companion Diagnostics: Growth and Growing Pains

article image

Uptake of companion diagnostics is increasing across oncology, with new diagnostic entrants, armed with next-generation technologies, seeking to upend the current, somewhat shaky business models with higher-value deals.

Companion diagnostics have certainly seen growing interest in recent years. This regulatory category establishes coordinated FDA review of a drug and an associated diagnostic test used to determine which patients are most likely to benefit from the drug.


This article is restricted to subscribers only.

Sign in to continue reading.


We're here to help! Please contact us at: